Treatment procedures and associated medical costs of methicillin-resistant infection in Japan: A retrospective analysis using a database of Japanese employment-based health insurance.

Clicks: 476
ID: 49287
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 5 articles by views in sage open medicine

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
This study aimed to determine the patient characteristics, treatment procedures, and medical costs of methicillin-resistant infections in clinical practice in Japan.Using the MinaCare database of healthcare information covering nearly 3 million individuals, of which 90% were aged 20-59 years, we extracted and analyzed data of patients who were aged ⩾15 years and diagnosed with methicillin-resistant during hospitalization between April 2010 and August 2015.A total of 684 patients with methicillin-resistant infection were listed in the database, of which 365 were eligible to be included in this study. Mean patient age was 52.9 years, and 31.5% of the patients were females. Methicillin-resistant bacteremia was the most common methicillin-resistant infection (32.9%) with a mean age of 48.5 years, followed by pneumonia (24.1%) with a mean age of 61.0 years and methicillin-resistant surgical site infection (6.3%) with a mean age of 49.7 years. Vancomycin was the most frequently prescribed anti-methicillin-resistant drug used as the first-line therapy (68.5%), followed by teicoplanin (14.2%), linezolid (7.9%), arbekacin (5.8%), and daptomycin (3.6%). The mortality rate was 11.0%, and the mean treatment duration was 13.3 days. The median total medical cost per patient was US$5083. The median treatment cost for methicillin-resistant bacteremia was the highest among the methicillin-resistant infections at US$9099, followed by methicillin-resistant pneumonia at US$3676 and surgery site infections at US$2084.Although the proportion of patients with methicillin-resistant is very small in the employment-based health insurance database, methicillin-resistant bacteremia is the most common methicillin-resistant infection in the working-age population and requires the highest medical cost. Methicillin-resistant pneumonia is more common in the elderly and is a cause of high mortality.
Reference Key
yuasa2019treatmentsage Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal sage open medicine
Year 2019
DOI
10.1177/2050312119871181
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.